Greenwich LifeSciences, Inc. GLSI
16.52 USD +1.35 (+8.90%)
At closeNov 9, 2026, 4:26 PM EST
16.52 0.00 0.00%
After hours · Nov 9, 4:26 PM ET
15.16 Day range 17.07
7.78 52-week range 34.10
- YTD
- -21.37%
- 1 year
- +90.76%
News
benzinga.com Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027 Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69 HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $50 to $69.
benzinga.com Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification.FLAMINGO-01 Steering Committee Clinical StrategyOn…- benzinga.com Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
benzinga.com Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial All European and US Sites to Treat Patients with Commercially Manufactured GP2The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023…- benzinga.com Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.31) by 87.1 percent. This is a 4.92 percent increase over losses…
benzinga.com Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026 from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's…
benzinga.com Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Greenwich LifeSciences Receives Nasdaq Noncompliance Notice Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast…
benzinga.com Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.- benzinga.com Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
- benzinga.com Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Greenwich Lifesciences' Preliminary Update Shows A Continued Reduction In The Recurrence Rate In The Fully Enrolled, 250-patient, Open-label Non-HLA-A*02 Arm Of FLAMINGO-01 Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…- benzinga.com Greenwich LifeSciences Says FDA Approves The First Commercial Lot Of GP2 Vials For Use In FLAMINGO-01 Study In U.S. STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,…
- benzinga.com Greenwich LifeSciences Says Cash on Hand Can Cover 2026 as Breast Cancer Trial Advances Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
benzinga.com Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday 
benzinga.com Greenwich LifeSciences Stock Jumps After FDA Update Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for…- benzinga.com Market-Moving News for January 22nd BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its in-house AI chipmaking unit, T-Head. GLSI: 65% | Greenwich LifeSciences Says FDA Clears First…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Greenwich LifeSciences Says FDA Clears First Commercial GP2 Lot for Phase III Breast Cancer Trial Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
benzinga.com Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
benzinga.com CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday - benzinga.com HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $50 HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $39 to $50.
benzinga.com What's Going On With Greenwich LifeSciences Stock Monday? Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its lock-up period to Sept. 30, 2026.
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com What's Going On With Greenwich LifeSciences Friday? Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streamlining its Phase 3 FLAMINGO-01 trial.
benzinga.com Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine? Greenwich LifeSciences stock rose after Phase 3 data showed GLSI-100 cut breast cancer recurrence rates by about 80% in new patients.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Greenwich LifeSciences Reports Early FLAMINGO-01 Results Showing 80% Reduction In Cancer Recurrences A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence rate shows an approximately 80% reduction in recurrence rate in the fully enrolled, 250 patient…
- benzinga.com Greenwich Lifesciences Completed Enrollment In Open-Label HLA-A*02 Arm of FLAMINGO-01 Phase 3 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types…
- benzinga.com Greenwich Lifesciences Announces Phase 3 FLAMINGO-01 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Has Achieved A Major Milestone By Screening Over 1,000 Patients Flamingo-01 Progress to DateThe Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the…
- benzinga.com Greenwich LifeSciences Strengthens European Presence As Flamingo-01 Clinical Trial Adds Belgium To Nine Approved Countries The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania,…
- benzinga.com Greenwich LifeSciences Takes Fight Against Breast Cancer Recurrence Global with Trial Expansion into Portugal Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com The FDA Has Granted Fast Track Designation To Greenwich Lifesciences' GLSI-100 In HLA-A*02 Patient Population Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
- benzinga.com Greenwich LifeSciences Cuts Costs by Bringing Breast Cancer Trial Management In-House Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
- benzinga.com Greenwich LifeSciences Expands Phase III Breast Cancer Trial Into Romania After Regulatory Green Light Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
- benzinga.com Greenwich LifeSciences Q1 EPS $(0.25) Down From $(0.19) YoY Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.25) per share. This is a 31.58 percent decrease over losses of $(0.19) per share from the same period last year.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $39 HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $38 to $39.
- benzinga.com Greenwich Lifesciences Provides Update On Its Phase III Clinical Trial, Flamingo-01, Which Is Evaluating GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences Flamingo-01 Progress to Date & Future PlansThe Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Greenwich Lifesciences Announces Immune Response Data From FLAMINGO-01 Phase 3 Clinical Trial FLAMINGO-01 Immune Response Data SummaryThe Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the…
- benzinga.com Greenwich LifeSciences Announced An Update On FLAMINGO-01 Open Label Safety Data FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $38 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $38 price target.